Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (111-120 of 536) with videos related to

Pageof 54
Sort By:
Blood|April 21, 2012
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaJosephine Aimiuwu, Hongyan Wang, Ping Chen, et al.
Genes, Chromosomes & Cancer|December 11, 2012
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461Alison Walker, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Leukemia Research|October 24, 2019
Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivationRyotaro Nakamura, Ketevan Gendzekhadze, Joycelynne Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemiaGuowei Dai, Kenneth K Chan, Shujun Liu, et al.
Pharmaceutical Research|March 18, 2009
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levelsPing Chen, Zhongfa Liu, Shujun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyAndreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 16, 2024
Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemiaDat Ngo, Jose Tinajero, Jianying Zhang, et al.
NPJ Systems Biology and Applications|March 26, 2024
Transcriptome free energy can serve as a dynamic patient-specific biomarker in acute myeloid leukemiaLisa Uechi, Swetha Vasudevan, Daniela Vilenski, et al.
British Journal of Haematology|August 24, 2019
Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemiaIbrahim Aldoss, Jianying Zhang, Raju Pillai, et al.
Blood|July 5, 2024
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemiaShanshan Suo, Dandan Zhao, Fenglin Li, et al.
Pageof 54

Showing results (111-120 of 536) with videos related to

Sort By:
Pageof 54
Blood|April 21, 2012
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaJosephine Aimiuwu, Hongyan Wang, Ping Chen, et al.
Genes, Chromosomes & Cancer|December 11, 2012
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461Alison Walker, Krzysztof Mrózek, Jessica Kohlschmidt, et al.
Leukemia Research|October 24, 2019
Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivationRyotaro Nakamura, Ketevan Gendzekhadze, Joycelynne Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemiaGuowei Dai, Kenneth K Chan, Shujun Liu, et al.
Pharmaceutical Research|March 18, 2009
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levelsPing Chen, Zhongfa Liu, Shujun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyAndreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 16, 2024
Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemiaDat Ngo, Jose Tinajero, Jianying Zhang, et al.
NPJ Systems Biology and Applications|March 26, 2024
Transcriptome free energy can serve as a dynamic patient-specific biomarker in acute myeloid leukemiaLisa Uechi, Swetha Vasudevan, Daniela Vilenski, et al.
British Journal of Haematology|August 24, 2019
Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemiaIbrahim Aldoss, Jianying Zhang, Raju Pillai, et al.
Blood|July 5, 2024
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemiaShanshan Suo, Dandan Zhao, Fenglin Li, et al.
Pageof 54